Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 10, Issue 2, Pages 360-367Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.27087
Keywords
Coxsackievirus A16 (CA16); neutralizing antibody; vaccine; animal model; recombination
Categories
Funding
- National 12th Five Major Special Projects Funding Program [2012ZX10004701]
- National High Technology Research and Development Program (863 program) from Ministry of Science and Technology of the People's Republic of China [2012AA02A402]
Ask authors/readers for more resources
Coxsackievirus 16 (CA16) is one of the major pathogens associated with hand, foot, and mouth disease (HFMD) in infants and young children. In recent years, CA16 and human enterovirus 71 (EV71) have often circulated alternatively or together in the Western Pacific region, which has become an important public health problem in this region. HFMD caused by CA16 infection is generally thought to be mild and self-limiting. However, recently several severe and fatal cases involving CA16 have been reported. Studies have shown that co-infection with CA16 and EV71 can cause serious complications in the central nervous system (CNS) and increase the chance of genetic recombination, which may be responsible for the large HFMD outbreak in Mainland China in 2008. For these reasons, recent studies have focused on the virological characteristics of CA16 and the development of CA16-related diagnostic reagents and vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available